The earnings call presented a mixed picture. While PureTech demonstrated strong financial health and promising developments in its core programs, the recent management changes and ongoing efforts to secure external funding introduce some uncertainties. Overall, the company's strategic initiatives and financial position suggest a cautiously optimistic outlook.

Company Guidance

During the PureTech Health 2025 Half Year Earnings Webcast, the company provided detailed guidance on its strategic priorities and financial metrics. PureTech emphasized its commitment to developing new treatments, highlighted by the clinical progress of its lead program, deupirfenidone (LYT-100), and the launch of new entities Celea Therapeutics and Gallop Oncology. The company outlined three strategic pillars: advancing patient-focused treatments, strengthening engagement with U.K. capital markets, and employing a disciplined capital allocation approach. PureTech plans to appoint two new nonexecutive directors to enhance its board's expertise in U.K. capital markets. Financially, PureTech reported cash and short-term investments totaling just under $320 million, with an operational runway extending well into 2028. The company is focused on leveraging external capital to fund its spinout entities while maintaining significant economic interests, exemplified by its 35.1% equity stake in Seaport Therapeutics, which recently had a post-money valuation of $733 million.

Strong Financial Position

PureTech ended the half year with cash, cash equivalents, and short-term investments of just under $320 million, providing operational runway well into 2028.

Positive Progress with Core Founded Entities

Celea Therapeutics, Gallop Oncology, and Seaport Therapeutics are progressing well. Seaport raised over $325 million and has a $733 million post-money valuation. Celea's deupirfenidone shows promising results for IPF treatment.

Significant Upside from Cobenfy Royalties

PureTech is entitled to 2% royalties on Cobenfy sales above $2 billion annually, with a potential value of around $300 million over time.

Operational Efficiency Improvements

Operational expenses reduced significantly, with operating expenses of just under $50 million in the first half of 2025, down from $66.7 million in the same period last year.

PureTech Health (GB:PRTC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:PRTC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 23, 2026	2025 (Q4)	-0.14 / -	0.267	―	―	―
Aug 28, 2025	2025 (Q2)	-0.15 / -0.14	-0.111	-26.67% (-0.03)	―	―
Apr 30, 2025	2024 (Q4)	-0.21 / 0.27	-0.111	340.00% (+0.38)	―	―
Aug 28, 2024	2024 (Q2)	-0.22 / -0.11	-0.067	-66.67% (-0.04)	―	―
Apr 25, 2024	2023 (Q4)	-0.24 / -0.11	-0.058	-92.31% (-0.05)	―	―
Aug 29, 2023	2023 (Q2)	>-0.01 / -0.07	-0.074	10.00% (<+0.01)	―	―
Apr 28, 2023	2022 (Q4)	0.03 / -0.06	0.037	-256.00% (-0.09)	―	―
Aug 25, 2022	2022 (Q2)	-0.20 / -0.07	-0.193	61.54% (+0.12)	―	―
Apr 26, 2022	2021 (Q4)	-0.18 / 0.04	-0.306	112.11% (+0.34)	―	―
Aug 24, 2021	2021 (Q2)	-0.17 / -0.19	0.311	-161.90% (-0.50)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:PRTC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 28, 2025	134.00p	126.60p	-5.52%
Apr 30, 2025	125.80p	123.00p	-2.23%
Aug 28, 2024	165.00p	169.60p	+2.79%
Apr 25, 2024	212.50p	212.50p	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PureTech Health PLC (GB:PRTC) report earnings?

PureTech Health PLC (GB:PRTC) is schdueled to report earning on Apr 23, 2026, TBA (Confirmed).

What is PureTech Health PLC (GB:PRTC) earnings time?

PureTech Health PLC (GB:PRTC) earnings time is at Apr 23, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of PureTech Health PLC stock?

The P/E ratio of PureTech Health is N/A.

What is GB:PRTC EPS forecast?

GB:PRTC EPS forecast for the fiscal quarter 2025 (Q4) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing